Considered a tumor suppressor, FOXO3A can regulate c‐Myc protein levels.[32] Deletion of FOXO3A accelerates lymphoma development in EμMYC mice.[33] In the clinic, higher FOXO3A levels predict better prognosis in colorectal cancer.[34] Additionally, elevated FOXO3A levels correlate with improved overall survival in the public DLBCL dataset [15b] (Figure S4B, Supporting Information). This evidence concerns the gene MYC and colorectal cancer.